Pink SheetHospital systems Bon Secours Mercy Health and the Cleveland Clinic told Senate investigators that they do not pass 340B drug discounts directly to patients because Congress did not design the 340B pro
Pink SheetAlyftrek (vanzacaftor/tezacaftor/deutivacaftor), Vertex Pharmaceuticals’ next generation treatment for cystic fibrosis (CF) is one of six orphan products that the European Medicines Agency backed for
Pink SheetThe European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc
Generics BulletinSamsung Bioepis has been a pioneer in the US biosimilar market since its first biosimilar Renflexis (infliximab-abda) was approved by the US Food and Drug Administration in 2017, but expensive develop